Global Allied Pharmaceuticals Corporation © 2019
Gastrointestinal Events Associated with Ipilimumab and combination therapies
Gastrointestinal Events Associated with Ipilimumab, Pazopanib, Anti PD1-
Antibody and Their Management: Single and Combination Therapies
Timothy Allen, MD, Ph.D1*, Giridhar M.N.V, MD,MBA1*, Ghazaleh Shoja E Razavi MD2
1Global Allied Pharmaceutical, Center for Excellence in Research & Development, USA.
2Dir. Clinical Development- Oncology and Respiratory, Global Allied Pharmaceutical, USA
*Corresponding author: Dr. Timothy Allen, MD, PhD, Global Allied Pharmaceutical, Center for Excellence in Research & Development,
USA, Tel: 321-945-4283; Email: Timothy.Allen@gapsos.com
Copyright: © 2015 Timothy
Cite this article: Timothy. Gastrointestinal Events Associated with Ipilimumab, Pazopanib, Anti PD-1 Antibody and Their Management: Single and Combination Therapies.
J J Vaccine Vaccination. 2015, 1(3): 011.
Immunotherapy of cancer has made significant advances in the past few years mainly due to the improved understanding of underlying principles of tumor pathology and immunology. Currently many malignancies are being treated by
Including malignant melanoma, advanced renal cell carcinoma (RCC), Non-small cell lung cancer, and prostate cancer. In these malignancies targeted therapies like multi kinase inhibitors also play an important role. These therapies are not without
significant adverse events. This article reviews gastrointestinal side effects reported with immunotherapeutic agents like ipilimumab, programmed death-1 (PD-1) antibody inhibitors and the multi-kinase inhibitor, pazopanib and their management.
Awareness and education of Health care professionals (HCPs) and patients are critical in identifying and managing
these adverse events. We have reviewed contemporary scientific literature and have summarized the results. Close monitoring and early treatment is of paramount importance in handling these event with the majority of events reversible or medically manageable per established treatment guidelines.
Keywords: Immunotherapy; Malignant Melanoma; Metastasis; T cells
List of Abbreviations
CTLA-4: Cytotoxic T-Lymphocyte Antigen-4;
RCC: Renal Cell Carcinoma;
irAE: Immune-Related Adverse Events;
mAbs; Monoclonal Antibodies;
TKIs: Tyrosine Kinase Inhibitors;
ALT: Alanine Trans Aminase;
PD-1: Programmed Death-1;
AEs: Adverse events